Effects of terguride in patients with Huntington's disease.
trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary movement performance was observed. However, in some patients, there was a slight improvement in patients' alertness and a reduction of the movement reaction time.
Stocchi
F
F
Department of Neuroscience, La Sapienza University, Rome, Italy.
Carta
A
A
Berardelli
A
A
Antonini
A
A
Argenta
M
M
Formica
A
A
Agnoli
A
A
D000328:Adult; D000339:Affect / Q000187:drug effects; D000368:Aged; D001364:Awareness / Q000187:drug effects; D002986:Clinical Trials as Topic; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008090:Lisuride / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D015259:Dopamine Agents; D004873:Ergolines; C006208:dironyl; D008090:Lisuride